CJC-1295* · DAC + No DAC*
Researchers seeking these products for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) used to investigate growth hormone signaling and regulation. The DAC and No DAC versions provide researchers with two different activity profiles, making them useful for studying both prolonged and shorter-duration GHRH signaling.
Research Benefits
GH & IGF-1 research – Investigates regulation of growth hormone and downstream IGF-1 signaling.
GHRH receptor research – Provides a model for studying GHRH receptor activity and endocrine signaling.
Extended-duration research – CJC-1295 DAC is designed to prolong peptide activity through its Drug Affinity Complex modification.
Shorter-duration research – CJC-1295 No DAC provides a model for studying more transient GHRH signaling.
Endocrine & metabolic research – Supports investigation of GH-related effects on metabolism, body composition, and cellular signaling.
Comparative pharmacology – The two forms allow researchers to investigate how peptide modifications can influence duration and pharmacokinetic behavior.
CJC-1295 DAC* · Drug Affinity Complex
CJC-1295 DAC is modified with a Drug Affinity Complex designed to extend its activity by promoting association with albumin in the bloodstream.
Research Benefits
Prolonged GH signaling – Studied for sustained increases in GH and IGF-1.
Extended pharmacological activity – Provides a longer-duration GHRH analogue for endocrine research.
Sustained signaling research – Allows comparison of prolonged versus transient GH activity.
Pharmacokinetic research – Useful for investigating how the DAC modification affects peptide duration and distribution.
Human endocrine research – Has been investigated in human clinical studies examining GH and IGF-1 responses.
Identified Risks & Side Effects
Metabolic effects – Changes in GH and IGF-1 can produce downstream metabolic effects.
Fluid retention – Edema and fluid retention have been reported in research.
Headache and related effects – Headache and other adverse effects have been reported in clinical research.
Glucose effects – Prolonged changes in GH signaling may influence glucose metabolism.
Long-term uncertainty – Long-term safety and therapeutic effectiveness remain insufficiently established.
Route: Experimental, commonly subcutaneous in research | Frequency: Varies by research protocol | FDA Status: Not FDA-approved
Researcher Note
The DAC modification is the defining feature of this version of CJC-1295. By extending activity, it provides researchers with a model for studying sustained GHRH, GH, and IGF-1 signaling.
CJC-1295 No DAC* · Modified GRF 1-29 / Mod GRF 1-29*
CJC-1295 No DAC, commonly marketed as Modified GRF 1-29 or Mod GRF 1-29, is a shorter-acting synthetic GHRH analogue. It provides a research model for investigating more transient GHRH and GH signaling.
Research Benefits
GHRH receptor research – Investigates interaction with GHRH receptors and downstream signaling.
GH secretion research – Provides a model for studying growth hormone release.
Pulsatile signaling research – Useful for investigating shorter-duration patterns of GHRH activity.
Endocrine research – Supports investigation of the GHRH-GH-IGF-1 axis.
Peptide pharmacology – Allows comparison of shorter-acting GHRH activity with DAC-modified compounds.
Identified Risks & Side Effects
Limited human evidence – Human clinical research specific to Modified GRF 1-29 remains limited.
Metabolic effects – Changes in GH and IGF-1 may produce downstream metabolic effects.
Fluid retention – Changes in GH signaling may contribute to fluid retention or edema.
Headache and flushing – These effects have been reported with GHRH/GH pathway compounds.
Long-term uncertainty – Long-term safety and therapeutic effectiveness have not been established.
Route: Experimental, commonly subcutaneous in research | Frequency: Varies by research protocol | FDA Status: Not FDA-approved
Researcher Note
The primary research distinction is duration of activity. CJC-1295 DAC is designed for prolonged activity, while Modified GRF 1-29 is studied as a shorter-acting GHRH analogue. Researchers should also be aware that terminology in the peptide marketplace can be inconsistent, and evidence for one form should not automatically be applied to the other.
Disclaimer
FDA Status: Not FDA-approved
Research Classification: Research use only
Compound Type: Synthetic GHRH analogues
All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.